CORONAVIRUS UPDATES
Find information and resources about the Research Institute's COVID-19 response
Rivella Laboratory
The Rivella Laboratory has expertise in the use of lentiviral vectors for modulation of gene expression and gene transfer for the cure of hemoglobinopathies, and in the pathophysiology and genetics of several murine models of hematopoiesis-, inflammation-, and iron-related disorders. Investigators in the lab are generating several lentiviral vectors aimed at curing beta-thalassemia and sickle cell anemia, and the team works with various murine models of hemoglobinopathies and patient cells to characterize these vectors.
The lab is also studying the role of seminal factors contributing to the morbidity and mortality in ß-thalassemia, polycythemia vera, and hemochromatosis; and in anemia of inflammation, such as hepcidin, intereleukin-2, ferroportin, the phosphokinase Jak2, and macrophages. Based on some of these studies, the lab is developing or contributing to the characterization of novel therapeutics.
Through a variety of novel technologies, Dr. Rivella and his team aim to treat and cure red blood cell disorders such as sickle cell disease and beta thalassemia. Learn about their ongoing work.
Leader
Stefano Rivella, PhD
Investigator
Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.
Cornerstone Blog
Stefano Rivella, PhD, is developing a new gene therapy — a multitasking vector — for treatment of red blood disorders.
Cornerstone Blog
The 2021 Distinguished Research Trainee Award recipients include trainees from a variety of levels and disciplines.
Cornerstone Blog
CHOP researchers have developed a potentially safer and more effective gene therapy vector for red blood disorders.